|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | |
| C07K 16/28 | |||
| G01N 33/569 |
| (11) | Number of the document | 2782599 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12795715.7 |
| Date of filing the European patent application | 2012-11-21 | |
| (97) | Date of publication of the European application | 2014-10-01 |
| (45) | Date of publication and mention of the grant of the patent | 2019-10-16 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2012/066345 |
| Date | 2012-11-21 |
| (87) | Number | WO 2013/078375 |
| Date | 2013-05-30 |
| (30) | Number | Date | Country code |
| 201161563430 P | 2011-11-23 | US | |
| 201261599221 P | 2012-02-15 | US |
| (72) |
BORIE, Dominique, US
HSU, Hailing, US
PAN, Wei-jian, US
REES, William, US
SULLIVAN, Barbara, US
|
| (73) |
Amgen Inc.,
One Amgen Center Drive Dept. 4300 M/S 27-4-A, Thousand Oaks, CA 91320-1799,
US
|
| (54) | ADMINISTRATION OF ALPHA4BETA7 HETERO-DIMER-SPECIFIC ANTIBODY |
| ADMINISTRATION OF ALPHA4BETA7 HETERO-DIMER-SPECIFIC ANTIBODY |